Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments (2010 - 2026)

Neurocrine Biosciences' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $259.2 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 13.05% year-over-year to $259.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 6.19% YoY) and the FY2025 annual result came in at $1.1 billion, up 12.6% from the prior year.
• Change in Acquisitions & Divestments was $259.2 million for Q1 2026 at Neurocrine Biosciences, down from $267.7 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $298.6 million in Q2 2025 and bottomed at $71.2 million in Q3 2022.
• A 5-year average of $223.5 million and a median of $250.8 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments slumped 55.42% — and 2023, when it soared 283.43%.
• Neurocrine Biosciences' Change in Acquisitions & Divestments stood at $162.2 million in 2022, then soared by 79.28% to $290.8 million in 2023, then declined by 13.76% to $250.8 million in 2024, then gained by 6.74% to $267.7 million in 2025, then declined by 3.18% to $259.2 million in 2026.
• Business Quant data shows NBIX's Change in Acquisitions & Divestments at $259.2 million in Q1 2026, $267.7 million in Q4 2025, and $225.0 million in Q3 2025.